Eastman Chemical EMN
- Market cap
- $7.4B
- PE
- 16.9×
- 10y median 13.4×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.8×
- EV/EBIT
- 20.7×
- Revenue, 12 months
- $8.9B
- −5% on a year ago
- Net margin
- 5.0%
- Free cash flow yield
- 7.3%
Eastman Chemical trades at 16.9× trailing earnings, pricier than 75% of the last ten years. Revenue was $8.9B over the last twelve months, down 5% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.3B−16% | $2.2B−7% | $2.3B−4% | $2.4B+2% | $2.5B+9% | $2.2B+2% | $2.3B−1% | $2.3B−3% | $2.2B−11% | $2B−12% | $2.2B−5% | $2.5B+10% | |
| Cost of revenue | $1.8B−18% | $1.7B−13% | $1.8B−6% | $1.8B+1% | $1.9B+4% | $1.7B−3% | $1.7B−3% | $1.8B+1% | $1.8B−5% | $1.6B−3% | $1.7B+1% | $2B+10% |
| Gross profit | $484M−11% | $464M+23% | $532M+1% | $599M+3% | $605M+25% | $554M+19% | $567M+7% | $506M−16% | $433M−28% | $338M−39% | $431M−24% | $560M+11% |
| R&D | $60M−12% | $57M−11% | $59M−5% | $60M+0% | $65M+8% | $66M+16% | $67M+14% | $67M+12% | $63M−3% | $58M−12% | $60M−10% | $65M−3% |
| SG&A | $160M−8% | $191M+11% | $191M+0% | $180M−3% | $183M+14% | $182M−5% | $182M−5% | $157M−13% | $160M−13% | $159M−13% | $178M−2% | $185M+18% |
| $266M−19% | $152M+30% | $276M+7% | $363M+6% | $332M+25% | $354M+133% | $310M+12% | $271M−25% | $191M−43% | $88M−75% | $201M−35% | $325M+20% | |
| Pre-tax income | $199M−29% | $425M+1418% | $214M+10% | $287M+7% | $280M+41% | $297M−30% | $253M+18% | $169M−41% | $134M−52% | $12M−96% | $136M−46% | $256M+52% |
| $20M | $114M+339% | $49M−18% | $56M | $99M+395% | −$34M | $70M+43% | $29M−48% | $87M−12% | −$93M+174% | $29M−59% | $72M+148% | |
| Net income | $178M−41% | $310M+30900% | $165M+23% | $230M−15% | $180M+1% | $330M+7% | $182M+10% | $140M−39% | $47M−74% | $105M−68% | $107M−41% | $183M+31% |
| $1.49−39% | $2.60+25900% | $1.39+24% | $1.94−15% | $1.53+3% | $2.83+9% | $1.57+13% | $1.20−38% | $0.40−74% | $0.92−68% | $0.93−41% | $1.59+33% | |
| 119M−3% | 119.1M−1% | 118.2M−1% | 118.6M−1% | 117.8M−1% | 116.7M−2% | 116.5M−1% | 116.2M−2% | 115.4M−2% | 114.4M−2% | 115M−1% | 115.3M−1% |
Operating income: 34 periods, Q1 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Eastman Chemical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EMNEastman Chemical | $7.4B | 16.9× | 13.4× | 0.8× | −5% | 5.0% | |
| ESIElement Solutions | $8.1B | 44.9× | 30.1× | 2.6× | +27% | 5.7% | |
| HXLHexcel | $6B | 40.0× | 35.9× | 3.0× | +5% | 7.8% | |
| BCPCBalchem | $5.6B | 34.8× | 41.0× | 5.2× | +9% | 15.1% | |
| ALBAlbemarle | $11.1B | 347× | 25.7× | 1.9× | +18% | 3.8% | |
| CSWCSW Industrials | $4.8B | 40.6× | 34.7× | 4.1× | +28% | 10.3% | |
| CBTCabot | $3.8B | 20.8× | 14.4× | 1.0× | −5% | 5.2% | |
| AVNTAvient | $3.8B | 22.2× | 20.2× | 1.1× | +2% | 5.1% | |
| DDDuPont de Nemours | $18.4B | 303× | 22.8× | 2.6× | +3% | 0.8% | |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | 4.2× | +10% | 13.2% | |
| FULFuller H B | $2.7B | 13.8× | 22.9× | 0.8× | +1% | 5.6% | |
| Peer median | $5.2B | 37.4× | 27.9× | 2.6× | +7% | 5.6% |
Investors who own it
Investors we follow who held Eastman Chemical at the end of Jun 30, 2026, from their 13F filings.
- Tom GaynerMarkel Group0.0% of portfolio
More on Eastman Chemical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 17Chemicals stocks with the lowest PE ratio
- #10of 26Chemicals stocks with the highest free cash flow yield
- #10of 13Chemicals stocks cheapest against their own PE history
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .